Zobrazeno 1 - 10
of 372
pro vyhledávání: '"Scott J. Antonia"'
Publikováno v:
APL Bioengineering, Vol 8, Iss 1, Pp 016120-016120-11 (2024)
Perfusable microvascular networks offer promising three-dimensional in vitro models to study normal and compromised vascular tissues as well as phenomena such as cancer cell metastasis. Engineering of these microvascular networks generally involves t
Externí odkaz:
https://doaj.org/article/2835ef51e4c44031a89f6c901b0cfcee
Autor:
Johan F. Vansteenkiste, MD, PhD, Jarushka Naidoo, MB, BCH, MHS, Corinne Faivre-Finn, MD, PhD, Mustafa Özgüroğlu, MD, Augusto Villegas, MD, Davey Daniel, MD, Shuji Murakami, MD, Rina Hui, M.B.B.S., PhD, Ki Hyeong Lee, MD, Byoung Chul Cho, MD, PhD, Kaoru Kubota, MD, PhD, Helen Broadhurst, MSc, Catherine Wadsworth, BVSc, Michael Newton, PharmD, Piruntha Thiyagarajah, MD, Scott J. Antonia, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100638- (2024)
Introduction: In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.00251) in patients with unresectable stage III NSCLC and no progression a
Externí odkaz:
https://doaj.org/article/86197b668ce247a6aed1dbb164a76e9d
Autor:
Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100337- (2022)
Introduction: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. Methods: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatmen
Externí odkaz:
https://doaj.org/article/4e8e10cbb46b4c6b9961babf7e012e44
Autor:
Theresa A. Boyle, Gwendolyn P. Quinn, Matthew B. Schabath, Teresita Muñoz‐Antonia, James J. Saller, Luisa F. Duarte, Laura S. Hair, Jamie K. Teer, Derek Y. Chiang, Rebecca Leary, Connie C. Wong, Alexander Savchenko, Angad P. Singh, LaSalette Charette, Kate Mendell, Gullu Gorgun, Scott J. Antonia, Alberto A. Chiappori, Benjamin C. Creelan, Jhanelle E. Gray, Eric B. Haura
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 225-237 (2020)
Abstract Background For the advancement of cancer research, the collection of tissue specimens from drug‐resistant tumors after targeted therapy is crucial. Although patients with lung cancer are often provided targeted therapy, post‐therapy spec
Externí odkaz:
https://doaj.org/article/82ae3eb5e1ff40e2b1ca8ba0ac5ee571
Autor:
Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm, Lawrence H. Schwartz, Boris Sepesi, Beow Yong Yeap, Naiyer A. Rizvi, Roy S. Herbst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-15 (2018)
Abstract Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable respon
Externí odkaz:
https://doaj.org/article/650b58462e0a46c6a4a982d979b2522c
Autor:
Melanie Mediavilla-Varela, Julio Castro, Alberto Chiappori, David Noyes, Dalia C. Hernandez, Bertrand Allard, John Stagg, Scott J. Antonia
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 7, Pp 530-536 (2017)
BACKGROUND: Therapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with various tumor types. The success of these studies has led to the development of various antibodies/inhibitors for the different
Externí odkaz:
https://doaj.org/article/1e09019f9dbb4076babae1b44dda43c7
Autor:
Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner, Ben C. Creelan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-6 (2017)
Abstract Background The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur. Case presentation We describe an autoimmune polymyositis following a partial res
Externí odkaz:
https://doaj.org/article/9f67bfe73bf84b4e86244989b2d24842
Autor:
Shailaja Raj, Marilyn M. Bui, Gregory Springett, Anthony Conley, Sergio Lavilla-Alonso, Xiuhua Zhao, Dungsa Chen, Randy Haysek, Ricardo Gonzalez, G. Douglas Letson, Steven Eric Finkelstein, Alberto A. Chiappori, Dmitry I. Gabrilovitch, Scott J. Antonia
Publikováno v:
Sarcoma, Vol 2015 (2015)
Purpose. Patients with large >5 cm, high-grade resectable soft tissue sarcomas (STS) have the highest risk of distant metastases. Previously we have shown that dendritic cell (DC) based vaccines show consistent immune responses. Methods. This was a P
Externí odkaz:
https://doaj.org/article/2afdf46826884423a98870f18301e1d6
Autor:
Hong Zheng, Xiaoqing Yu, Mohammed L. Ibrahim, Dana Foresman, Mengyu Xie, Joseph O. Johnson, Theresa A. Boyle, Brian Ruffell, Bradford A. Perez, Scott J. Antonia, Neal Ready, Andreas N. Saltos, Mark J. Cantwell, Amer A. Beg
Publikováno v:
Cancer Immunology Research. 11:466-485
Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membran
Autor:
Alexandra L. Martin, Chase Powell, Mate Z. Nagy, Patrick Innamarato, John Powers, Derek Nichols, Carmen M. Anadon, Ricardo A. Chaurio, Sungjune Kim, Min-hsuan Wang, Bing Gong, Xianzhe Wang, Thomas J. Scheutz, Scott J. Antonia, Jose R. Conejo-Garcia, Bradford A. Perez
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1445-1460